Part 4 of 4: Jon Chee hosts Chris Moxham, Co-Founder, CEO, and CSO of Transcripta Bio—a pioneering biotech company accelerating drug discovery to improve lives worldwide.
With a PhD in Molecular and Cellular Pharmacology from Stony Brook University and over 25 years in drug discovery, Chris brings a wealth of experience. During his two-decade tenure at Eli Lilly, he advanced over 10 molecules into clinical trials across multiple therapeutic areas, spanning both small and large molecule modalities.
Chris’s deep expertise and dedication to scientific innovation and team development offer invaluable insights for aspiring biotech leaders.
Join us this week to hear about:
- The complexities of building partnerships with Big Pharma as a startup
- Insights on developing relationships with larger organizations and patient foundations
- The importance of mutual goals and the art of aligning incentives
- Transcripta’s progress with their groundbreaking Drug-Gene Atlas, combining genetics, AI, and high-throughput data to redefine the future of drug discovery
Please enjoy Jon’s conversation with Chris Moxham.
Find Our Guest, Chris Moxham, at these links:
Find Our Host, Jon Chee, at these links:
Excedr Socials & Website
Enriched Notes:
Topics Mentioned:
People Mentioned:
Timestamps:
00:00 Intro and recap
02:09 Partnering with Big Pharma and the urgency of startups
04:13 Learning business development and building successful partnerships
06:18 Understanding stakeholder involvement and approval layers in Big Pharma
09:42 Transcripta's collaborations with patient foundations and medical institutions
11:31 Ideal partnerships with academic institutions and aligning incentives
15:53 The importance of partnership alignment, building trust within the org
20:47 Transcripta Bio's vision for the future
21:52 Shoutouts and advice to younger self
24:45 Outro
The Biotech Startups Podcast is handcrafted by our friends over at:
fame.so